p53與IMP1自體抗體作為食道癌與子宮內膜異位症腫瘤標記之研究

Study of p53 and IMP1autoantibody as tumor markers in human esophageal cancer and Endometriosis

趙俊欽(Chun-Chin Chao)

指導教授 ： 陳凌雲

中山醫學大學/醫學科技學院/生物醫學科學學系碩士班/碩士(2009年)

https://doi.org/10.6834/CSMU.2009.00061

摘要

食道癌在台灣十大癌症死亡原因中排名第九位，大多數患者到晚期才被確立診斷，往往造成預後不佳的情況，故食道癌早期的診斷具有重要的意義。另外，雖然子宮頸癌、卵巢癌一直在女性癌症死亡原因中名列前矛，但卻以子宮內膜異位症、子宮肌腺症及子宮肌瘤等較為常見，大多數病患透過手術去除病痛，但其復發率甚高，且發現復發時已為時已晚，故早期診斷及預後之指標具有重大之意義。早期學者採用SEREX方法檢測出癌症患者的血清中有抗體可以辨識腫瘤相關抗原(tumor-associated antigen)，大部分的腫瘤相關抗原的基因由於癌症而導致突變或不正常的表現，因此偵測這些腫瘤抗原之自體抗體可成為腫瘤形成時的標記。本論文製備本實驗室王世吉學長與蘇家鈴學姐已完成之8個腫瘤相關抗原：IMP1、p53、Cyclin B1、Ras、CSK、Erbb2、p90和p16，以酵素免疫法偵測66位ㄧ般女性與38位一般男性血清中IMP1、p53、Cyclin B1、Ras、CSK、Erbb2、p90及p16八個抗原之自體抗體並計算出現率。結果發現以p53、Csk、p90、p16無論男女其表現量都高。挑選一般男性陽性率較低之 p53(10.5%)偵測126位男性食道癌病患血清中之自體抗體，病患之陽性率高達26%，這樣的結果似乎表示p53可能可作為食道癌之腫瘤標記。所以將一般男性檢體再放大至70位並重新計算一般男性與病患之陽性率，結果一般男性從10.5%上昇至18%，病患從26%下降至21%，由於一般男性與食道癌病患的陽性率相差不大，故p53並不適合作為食道癌之腫瘤標記。另外選取一般女性陽性率幾乎為0%的IMP1、Cyclin B1二個腫瘤相關抗原偵測56位子宮相關疾病病患血清中之自體抗體。結果IMP1陽性率14.29%與一般女有所差異。而Cyclin B1陽性率1.78%與一般女性差異性不大。故IMP1適合做為子宮相關疾病之腫瘤標記。

關鍵字

腫瘤標記

並列摘要

The esophagus cancer ranks the ninth in the ten greatest cancers in Taiwan, most patient would be established diagnosis until later period, poor condition after usually causing to prepare, the diagnosis esophagus cancer in earlier period is important. Cervical cancer, ovary cancer rank in the ten greatest cancer of female, but endometriosis、adenometriosis and myoma always occur in female .So diagnose in early and the index sign after preparing has great significance. In early the method of SEREX to detect that the antibody of the cancer serum can recognize the tumor associated antigen(TAA), the most tumors related antigen caused because of cancer mutation, therefore detect these TAA from the autoantibody can become mark when the tumor become . The eight tumor associated antigens:IMP1,p 53, Cyclin B1, Ras, Csk, Erbb2, p90 and p16, detect the autoantibody of 66 general females and 38 general males with ELISA and the positive, The result finds that the same TAA to autoantibody is is different on the sex, among the p16 no matter males and females its autoantibodyall is high.Choose the general male positive rate lower p53(10.5%) and detect the autoantobody of esophagus cancer of 126 males patient, and calculate the positive . The result suggests that the patient's positive rate is up to 26%, in other words p53 probably be the tumor marker in esophagus cancer.But the general male is too few to be enough to stand for great male, so enlarge to 70 .The result that the general down to 18%, the patient rise to 21%, so p53 can`t be used as tumor marker in esophagus cancer. Another,choosing the IMP1 and Cyclin B1 and detect the autoantibody of 56 gynecological patient and calculate the positive. The result suggest that IMP1 positive rate 14.29%, so IMP1 a can be used as tumor marker in gynecological disease .

並列關鍵字

tumor marker

參考文獻

Akahane T, Sekizawa A, Purwosunu Y, Nagatsuka M, Okai T.(2007) The role of p53 mutation in the carcinomas arising from endometriosis. Int J Gynecol Pathol. 26, 345-51.

Arinaga, M., Noguchi, T., Takeno, S., Chujo, M., Miura, T., Kimura, Y., and Uchida, Y. (2003). Clinical implication of cyclin B1 in non-small cell lung cancer. Oncol Rep 10, 1381-1386.

Adari, H., Lowy, D. R., Willumsen, B. M., Der, C. J., and McCormick, F. (1988). Guanosine triphosphatase activating protein (GAP) interacts with the p21 ras effector binding domain. Science 240, 518-521.

Armstrong, E., Cannizzaro, L., Bergman, M., Huebner, K., and Alitalo, K. (1992). The c-src tyrosine kinase (CSK) gene, a potential antioncogene, localizes to human chromosome region 15q23----q25. Cytogenet Cell Genet 60, 119-120.

Bougeret, C., Jiang, S., Keydar, I., and Avraham, H. (2001). Functional analysis of Csk and CHK kinases in breast cancer cells. J Biol Chem 276, 33711-33720.